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Abstract
Background: Ascites is the most common complication of cirrhosis. It may lead to the consequence of poor
prognosis and the deterioration of quality of life. Asopressin V2 receptor antagonists is a kind of vaptans, and it has
been proved to be effective in hyponatremia patients. We conducted a meta-analysis about treatment of vaptans in
cirrhosis patients with ascites.
Methods: Following our selection criteria, we collected a total of 14 studies containing 16 randomized controlled
trials (2620 patients) from a series of database about the treatment with vaptans for cirrhosis with ascites patients.
The included studies compared the treatment effect of lixivaptan (VPA 985), or RMJ-351647, or satavaptan, or
tolvaptan with placebo.
Results: The included vaptans (asopressin V2 receptor antagonists) showed significant effect of increasing the
serum sodium concentration for cirrhosis patients (WMD = 2.11 mmol/L, p < 0.00001). Patients also could acquire
significant improvement of ascites, as this kind of aquaretics can significantly reduce ascites patients’ weight
(WMD = −1.53, p < 0.00001), abdominal girth (WMD = −2.04, p < 0.00001), and the ratio of worsening ascites
(RR = 0.51, p = 0.001). Though the drug did not produce more total adverse events (RR = 1.04, p = 0.09) and the
total serious events (RR = 1.04, p = 0.42), the emergence of excessive correction of serum sodium concentrations
(>145 mmol/L) was more frequently noted in patients under the employment of vaptans (RR = 2.14, 95 %
CI [1.45, 3.16], p = 0.0001). Whether with the administration of vaptans for short-term or long-term, no survival
benefit was detected from the selected studies.
Conclusions: Asopressin V2 receptor antagonists could play an effective and safe role in symptomatic treatment
for cirrhosis patients with ascites, especially for refractory ascites patients who presented insufficient response to
conventional diuretics.
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Background
As the most common complication of cirrhosis, ascites
is occurred in about 60 % patients within 10 years
during the course of compensated cirrhosis [1]. Besides
the consequence of poor prognosis, persistent ascites
may lead to the development of various subjective and
objective symptoms, which could result in deterioration
of quality of life (QOL) [2]. Besides the liver transplantation,
diuretics also play an important role on the conventional
management of ascites, such as aldosterone antagonist
(spironolactone) and loop diuretic (furosemide) [3]. But the
effect is complicated for the cirrhosis patients due to the
varied response to these diuretics [4]. If we administrate
diuretics with high dose to achieve a higher response,
complications, which are associated with diuretics, could
develop more frequently, like electrolyte disturbances,
worsening of renal function, hepatic encephalopathy, and
so on [5, 6]. On account of these reasons, the development
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of more effective drugs for the management of ascites is
necessary.
The orally and intravenously active non-peptide
vasopressin receptor antagonists are called vaptans.
Vasopressin V2 receptor antagonists are one of the
three kinds of vaptans, and they could competitively
bind and block the V2-receptors of arginine vasopressin
(AVP) in the renal collecting ducts. So unlike the
traditional diuretics, they could induce a highly hypotonic
diuresis without affecting the excretion of electrolytes [7].
Previous reports found it was effective to improve the
serum sodium concentration of hyponatremia, which was
generated from syndrome of inappropriate antidiuretic
hormone secretion (SIADH), congestive heart failure
patients, and cirrhosis patients with ascites, especially
[8, 9]. Some drugs have been approved for the treatment
of hyponatremia in Europe [3]. However, some aspects
limit the use of vasopressin V2 receptor antagonists.
Excessive correction of hyponatraemia, which could
be produced by aquaretics, may cause some serious
consequence, like osmotic demyelination and myelinolysis;
Liver injury is another serious problem people concern
with, which is regarded as an important adverse effect
from the use of vaptans [10]. In addition to these, there
are still some uncertainty and controversies about the
effectiveness of vaptans on improvement of the symptoms,
prognosis of the cirrhosis patients with ascites. We
systematically reviewed the previous randomized controlled
trials about the treatment of vasopressin V2 receptor
antagonists in cirrhosis patients with ascites.
Methods
Search strategy
We searched the studies till February 2014 from the follow-
ing databases: MEDLINE, PubMed, Embase, the Cochrane
Centeral Register of Controlled Trials, Cochrane Database
of Systematic Reviews, http://www.ClinicalTrials.gov, and
the Chinese BioMedical Literature Database. At the mean
time, we check the references of some relevant previous
studies to make sure no eligible studies were missed. The
searching language was English or Chinese, and the search
terms were: vasopressin V2 receptor antagonist, vaptans,
mozavaptan, OPC 31260, satavaptan, lixivaptan, VPA 985,
RMJ-351647, cirrhosis, liver fibrosis, ascites, hepatic edema,
hyponatremia.
Selection criteria
In our selection process, randomized controlled trials
focusing on the treatment for ascites patients with all
kinds of of vasopressin V2-receptor antagonist were
included (Fig. 1). These adopted vaptans included tolvap-
tan, conivaptan, lixivaptan (VPA-985), mozavaptan, sata-
vaptan, RMJ-351647. Although conivaptan is antagonists
of vasopressin V1A and V2 receptors, it was also included.
All patients in the selected studies should be definitely
diagnosed as ascites, and the disease of cirrhosis should be
the only pathogeny. Whether patients accepted conven-
tional diuretics before or during the study, they would be
included.
And the exclusion criteria were: (1) nonhuman studies;
(2) non-randomized trials; (3) articles not containing
Fig. 1 Identification process of the included studies
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primary data or not stating the data of cirrhosis patients
separately; (4) patients with other diseases which also
could cause ascites, like SIADH, liver failure, kidney
disease; (5) patients with other serious disease, such
as neoplastic disease, the end stage of other chronic
disease, and severe nervous system disease.
Data extraction and quality assessment
Two authors independently extracted the data with
the tool of Microsoft Office Excel. In this process, the
included articles were further checked once more and
some studies were excluded for the reason that the
data did not meet the inclusion criteria. Following a
brief plan which was made previously, the two authors
collected the publication details, study characteristics, and
the data of outcome assessment. Discrepancies were
resolved by discussion until a consensus was made.
The quality assessment of all eligible studies was carried
out with the Jadad score (maximum number of points is
5). This evaluation criterion is based on the description of
three aspects in the study: random approach, blind
method, the withdrawals and dropouts. And each of the
first two aspects had totally 2 points and the third had just
1 point [11]. Studies with 3 points or above 3 points were
considered with high quality. Sensitivity analysis was
presented as performing the fixed effects model and
the random effects model meta-analyses at the same
time and observing whether the conclusions differed
from each other [12]. Publication biases were assessed
with funnel plots.
Outcome Measures and statistical analysis
We assessed the extracted data about the efficacy and safety
to synthetically evaluate the treatment of included vaptans
for cirrhosis patients with ascites. All included vaptans
(tolvaptan, conivaptan, lixivaptan/VPA-985, mozavaptan,
satavaptan, RMJ-351647) adopted in these selected studies
were regarded as one drug when we analyzed the data.
And there just would be one vaptans used in one study.
The primary outcomes measure was survival rate.
Secondary outcomes for assessing the efficacy contained
the improvement of serum sodium (change of serum
sodium concentration, normalized ratio of serum sodium
concentration), the improvement of ascites (change of
weight and abdominal girth). The occurrence of adverse
events, which contained thirsty, excessive correction of
serum sodium concentrations and the complications
of liver cirrhosis, was assessed to evaluate the safety
of vasopressin V2 receptor antagonists for cirrhosis
patients with ascites.
Review Manager 5 was mainly used to conduct the
statistical analysis, and SPSS 20 was also used if neces-
sary. All of the analysis work was carried out according
to the Cochrane Handbook of Systematic Reviews of
Interventions [12]. If there were several dose groups
comparing with one control group, the data of interven-
tion groups would be gathered up as one to make the
comparison of dichotomous variables, and the highest
dose group would be regarded as the only drug interven-
tion group when we analyzed continuous variables.
Dichotomous variables (normalized ratio of serum sodium
level, adverse events, and 1-year survival) were expressed
as odds ratios (OR) or risk ratio (RR)with 95 % confidence
interval (CI), continuous variables were presented as
weighted mean differences (WMD) with 95 % CI. When
we pooled the data across studies, fixed-effects model was
used in most cases, and random-effects model was
adopted when statistical heterogeneity was significant. I2
was calculated in the process of analysis, which was used
to assess the statistical heterogeneity [13]. We defined
0-25 % as no or low-level heterogeneity, > = 50 % as
significant heterogeneity. When the heterogeneity was
significant, we would adopt subgroup to analyze the data




A total of 14 studies containing 16 RCTs and 2620 patients
met our selection criteria and were selected [14–27]. Since
the study reported by Florence Wong [22] had three trails,
all of which separately compared satavaptan with placebo,
each trail was considered as an independent RCT
when we analyzed the data. Most of selected studies were
multicentre. Though 3 studies [25–27] were published as
abstract, they were also included for containing important
survival data. Among the 16 RCTs, there were 3 comparing
lixivaptan (VPA 985) with placebo [14–16], 1 comparing
RMJ-351647 with placebo [17], 9 comparing satavaptan
with placebo [18–20, 22, 25–27], and 3 comparing tolvap-
tan with placebo [21, 23, 25]. Conventional diuretics was
not used in 2 RCTs [14] [22]. In the rest of selected studies,
whether patients in the vaptans arm or in the placebo arm,
they would get spironolactone or/and furosemide if
doctors considered they had to. Patients adopted sodium-
restricted diet in all of the studies if necessary. The basic
characteristics of all included studies were presented in
Table 1.
Quality assessment
When we used Jadad score (maximum number of points
is 5) to assess the quality of these selected 16 RCTs
(14 studies) basing on their descriptions in the articles, 8
got 5 points [15, 18–22], 5 got 4 points [14, 16, 17, 23, 24],
and 3 got 3 points [25–27]. Most of the RCTs were
double-blinding (81 %). 50 % of all the 16 RCTs calculated
the sample size before the studies.
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Table 1 Characteristics of included studies
Study Country Study
design












Multicenter trail RCT NA Double-blind 1 d N palcebo 5 55.6 ± 10.1 3/2 139.0 ± 3.2
VPA-985 25 mg 4 58.5 ± 9.5 3/1 140.5 ± 2.1
VPA-985 50 mg 5 59.4 ± 6.0 5/0 135.7 ± 5.2
VPA-985 100 mg 4 61.2 ± 8.0 3/1 131.0 ± 6.0
VPA-985 200 mg 4 62.8 ± 5.8 3/1 139.0 ± 3.0
VPA-985 300 mg 5 49.0 ± 2.9 4/1 136.0 ± 2.1
2 Alexanderl.
Gerbes (2003)
Multicenter trail RCT Computerized
randomization
Double-blind 7 d NA palcebo 20 58 ± 2 15/5 127.3 ± 3.0
VPA-985 100 mg/d 22 54 ± 3 17/5 128.3 ± 4.1
VPA-985 200 mg/d 18 56 ± 3 14/4 126.4 ± 4.4
3 Florence Wong (2003) Multicenter trail RCT Computerized
randomization
NA 7 d Y palcebo 8 NA NA 127 ± 1
VPA-985 50 mg/d 8 126 ± 1
VPA-985 250 mg/d 10 122 ± 2
VPA-985 500 mg/d 7 125 ± 1
4 PJ THULUVAT H (2006) USA RCT NA Double-blind 1 d Y palcebo 6 50.5 ± 7.6 4/2 136 ± 2
RWJ-351647 1 mg 6 56.5 ± 5.2 4/2 136 ± 5
RWJ-351647 2 mg 6 51.5 ± 7 5/1 137 ± 2
RWJ-351647 5 mg 6 48.3 ± 1.2 5/1 136 ± 3
5 Pere Gines (2008) Multicenter trail RCT Computerized
randomization
Double-blind 14 d Y palcebo 28 55 ± 10 22/6 NA
Satavaptan 5 mg/d 28 57 ± 8 16/12
Satavaptan 12.5 mg/d 26 56 ± 9 19/7
Satavaptan 25 mg/d 28 59 ± 10 20/8
6 Florence Wong (2010) Multicenter trail RCT Computerized
randomization
Double-blind 12 weeks Y palcebo 36 60 ± 9 26/10 136 ± 4
Satavaptan 5 mg/d 39 59 ± 9 32/7 133 ± 6
Satavaptan 12.5 mg/d 36 59 ± 9 28/8 135 ± 5
Satavaptan 25 mg/d 40 60 ± 11 29/11 134 ± 5
7 Pere Gines (2010) Multicenter trail RCT Computerized
randomization
Double-blind 14 d Y palcebo 35 58 ± 9 22⁄13 137 ± 3
Satavaptan 5 mg/d 40 58 ± 9 30⁄10 137 ± 3
Satavaptan 12.5 mg/d 35 57 ± 8 26⁄9 136 ± 4
Satavaptan 25 mg/d 38 55 ± 9 25⁄13 136 ± 2
8 Andres Cardenas (2012) USA RCT Stratified random Double-blind 30 d Y Placebo 57 55 ± 9 38/19 NA
Tolvaptan 15-60 mg/d 63 52 ± 8 50/13












Table 1 Characteristics of included studies (Continued)
Satavaptan
5 or 10 mg/d
232 56.6 ± 10.2 158/74
9b Florence Wong (2012)b Multicenter trail RCT Stratified random Double-blind 52 weeks Y placebo 168 57.0 ± 9.8 113/55 NA
Satavaptan
5 or 10 mg/d
328 58.9 ± 10.0 237/91
9c Florence Wong (2012)c Multicenter trail RCT Stratified random Double-blind 52 weeks N placebo 80 56.2 ± 9.9 50/30 NA
Satavaptan
5 or 10 mg/d
160 56.4 ± 9.6 108/52
10 Isao Sakaida (2014) Japan RCT NA Double-blind 7 d Y placebo 80 NA 49/31 135.7 ± 4.1
tolvaptan
7.5 mg/d
82 52/30 135.3 ± 4.5
11 Kiwamu Okita (2014) Japan RCT NA Double-blind 7 d Y placebo 26 64 ± 10 17/9 NA
tolvaptan
7.5 mg/d
25 65 ± 9 18/7
tolvaptan
15 mg/d
25 65 ± 10 21/4
tolvaptan
30 mg/d
25 63 ± 10 15/10























Effects of vasopressin V2-receptor antagonist
The effects of vasopressin V2-receptor antagonist for
cirrhosis patients with ascites were assessed by analyzing
the improvement of ascites and serum sodium, changes
of other correlative laboratory tests, and survival data
from selected studies.
The improvement of ascites
The change of weight and abdominal girth was usually
used to assess the effectiveness of the treatment for
ascites. The mean change of weight and abdominal girth
was measured as the ending data minus the baseline
data (more negative represented more decrement). After
pooling and analyzing the change of weight, we found
patients in vaptans arm reduced more than in placebo
arm after 7-days [23, 24] and 14-days [18, 20] both
(WMD= −1.46Kg, 95 % CI [−1.95,-0.97], p < 0.00001 and
WMD= −1.98Kg, 95 % CI [−3.24,-0.72], p = 0.002, Fig. 2a).
Two studies [23, 24] supplied the information of the mean
change of abdominal girth after 7 days of intervention,
and patients in vaptans arm were found to be more
decrement (WMD = −2.04 cm, 95 % CI [−2.94,-1.14],
p < 0.00001, Fig. 2b). When we defined ascites worsening
as either need for therapeutic paracentesis, increase in
diuretic dose or weight gain of > =2 kg during the study
period [18, 20], we found the ratio of worsening ascites
was lower by the employment of vaptans (RR = 0.51, 95 %
CI [0.34, 0.77], p = 0.001).
The obvious reduction of weight and abdominal girth
followed the significant effect of promoting renal water
excretion of vaptans. Except three studies, which were
published as abstract, all of the other studies reported
vaptans could significantly increase ascites patients’ 24 h
urine output compared with placebo, whether patients
in the two controlled groups taking conventional diuretic
(spironolactone, or furosemide) or not during studies.
This effect appeared from the first dose of vaptans, and it
seemed as dose-dependent [14, 15, 17, 18, 20]. That meant
within the scope of the adopted dose of vaptans in all
studies (lixivaptan/VPA-985 was 25 mg, 50 mg, 100 mg,
200 mg, 300 mg per day, or 100 mg, 200 mg per day;
RWJ-351647 was 1 mg, 2 mg, 5 mg per day; satavaptan
Fig. 2 a The comparison between the vaptans groups and placebo groups about the mean change of weight after 7-days and 14-days intervention.
Studies are identified by the first author’s full name and year of publication. Weighted mean differences are pooled using the fixed effects model.
Abbreviation: SD, standard deviation; CI, confidence interval. b The comparison between the vaptans groups and placebo groups about the mean
change of abdominal girth after 7-days intervention. Studies are identified by the first author’s name and year of publication. Weighted mean
differences are pooled using the fixed effects model. Abbreviation: SD, standard deviation; CI, confidence interval
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was 5 mg, 12.5 mg, 25 mg per day), higher dose could
bring larger rise of urine.
The improvement of serum sodium
Just short-term data (1-14d) about the change of serum
sodium concentration of ascites patients could be
available according to the extracted information. 6
studies (containing 360 patients) [15–17, 19, 20, 23]
reported the baseline and ending serum sodium concen-
tration both, and we separately compared these two
groups of data to detect the effects of intervention
measures. Even patients in the vaptans arm had a lower
baseline of serum sodium concentration than in the
control arm with placebo (WMD= −1.28 mmol/L, 95 %
CI [−1.89, −0.68], p < 0.0001, Fig. 3a), when comparing the
ending data, the patients in vaptans arm had higher serum
sodium concentration (WMD= 2.72 mmol/L, 95 % CI
[0.49, 4.94], p = 0.02, Fig. 3b). As the heterogeneity was
88 % (>50 %), the random-effects model was used when
comparing the ending data. In these 6 studies, most
patients had gotten spironolactone or/and furosemide if
necessary except the patients in 1 study. This one did not
refer to the use of conventional diuretics, and when we
removed this 1 exception, the result of analysis was
basically the same. So from the outcome of analysis,
we found short-term application of vaptans on the basis of
using conventional diuretics could more significantly
improve the serum sodium concentration of cirrhosis
patients with ascites than application of conventional
diuretics only.
There were 3 studies [15, 23, 24] offered information
of the mean change between baseline and ending serum
sodium concentration after using vaptans for 7 days. We
got the same conclusion that patients in vaptans arm
obtained larger improvement in serum sodium concentra-
tion during the studies than patients in the placebo group
(WMD= 2.11 mmol/L, 95 % CI [1.31, 2.92], p < 0.00001,
Fig. 3c), which meant vaptans could contribute to recover
the patients’ serum sodium concentration with ascites.
The normalization ratio of serum sodium (normal
value was defined as > =136 mmol/L) after treatment of
vaptans within 1 week (4, 5, 7d) were mentioned in
3 studies [15, 18, 21]. The analysis result told that
vaptans were significant helpful in normalizing ascites
patients’ serum sodium concentration (OR = 7.43, 95 % CI
[3.71, 14.89], p < 0.00001, Fig. 3d)
Survival
Three studies containing five RCTs (1571 patients)
reported the information of 1-year survival after the
intervention of vaptans or placebo for cirrhosis patients
with ascites [22, 26, 27]. However, the analysis result of
survival was inconsistent with the effects of relieving asci-
tes symptoms and elevating serum sodium concentration
which were mentioned above. Vaptans did not extend
patients’ lifetime comparing to the placebo (OR = 0.89,
p = 0.32). In order to eliminate the influence of con-
ventional diuretics (spironolactone or/and furosemide)
to vaptans, we established two subgroups according to
whether the included studies treated patients (both vaptans
and placebo groups) with conventional diuretics or not. It
seemed both two subgroups (patients getting conventional
diuretics or not), the included vaptans did not extend
patients’ lifetime (p = 0.16, and p = 0.06, Fig. 4). There also
were 3 studies (419 patients) mentioned the survival after
short-term (2, 4, 12 weeks) administration of vaptans, and
as the same with long-term survival, no increase or drop of
mortality in the vaptans groups was found versus placebo
patients in these studies (OR = 1.09, p = 0.85).
Safety
We assessed the safety of all these studies by analyzing
the incidence rate of adverse events, which occurred
during researches. Adverse events mainly presented as
general events, like thirsty, and serious events, which
mostly was the severe manifestations and complications
of liver cirrhosis.
Though the incidence of adverse events were light
higher in the vaptans groups following short-term
(1d-3 months) intervention (RR = 1.11, 95 % CI [1.01,
1.23], p = 0.03), there was no significant difference between
the two groups about the total adverse events (RR = 1.04,
p = 0.09, Fig. 5a). The occurrence of the total serious events
was almost the same between vaptans and placebo arms
(RR = 1.04, p = 0.42), no matter the intervention time was
short (p = 0.61) or long (p = 0.52, Fig. 5b). More patients
would likely feel thirsty after taking vaptans than patients
with placebo (RR = 7.02, 95 % CI [3.04, 16.19], p < 0.00001).
Excessive correction of serum sodium concentrations
(the serum sodium level was >145 mmol/L after the use
of vaptans) was more frequently noted in patients
under the employment of vaptans (RR = 2.14, 95 % CI
[1.45, 3.16], p = 0.0001). Some serious events, which
were the complications of liver cirrhosis, like gastrointes-
tinal bleeding (p = 0.09), renal impairment (p = 0.16),
hepatic encephalopathy (p = 0.70), emerged in the same
between experimental and control patients. We considered
hepatic failure, hepatorenal syndrome, veno-occlusive liver
disease, hepatic encephalopathy, and the increase of
blood bilirubin as the deterioration performances of liver
function. There was no significant difference about the
incidence rate of deterioration of liver function between
the patients who adopted vaptans or not.
Almost all studies found the administration of the
included vasopressin V2-receptor antagonist had fewer
clinically significant changes of heart rate and blood pres-
sure, which suggested the significant effect of diuresis
would not affect the cardiovascular function.
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Fig. 3 a The comparison between the vaptans groups and placebo groups about the mean of baseline serum sodium concentration before
interventions. Studies are identified by the first author’s name and year of publication. Weighted mean differences are pooled using the fixed
effects model. Abbreviation: SD, standard deviation; CI, confidence interval. b The comparison between the vaptans groups and placebo groups
about the mean of ending serum sodium concentration after short-term (1-14d) interventions. Studies are identified by the first author’s name
and year of publication. Weighted mean differences are pooled using the random effects model. Abbreviation: SD, standard deviation; CI, confidence
interval. c The comparison between the vaptans groups and placebo groups about the mean change of serum sodium concentration after 7 days
interventions. Studies are identified by the first author’s name and year of publication. Weighted mean differences are pooled using the random effects
model. Abbreviation: SD, standard deviation; CI, confidence interval. d The comparison between the vaptans groups and placebo groups about the
normalization ratio of serum sodium concentration within 1 week (4, 5, 7d) interventions. Studies are identified by the first author’s name and year of
publication. The Odds Ratios are pooled using the fixed effects model. Abbreviation: CI, confidence interval
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Sensitivity analysis and Publication bias
The sensitivity analysis was carried out in every meta-
analysis mentioned above by performing the fixed effects
model and the random effects model meta-analyses at
the same time and observing whether the conclusions
differed from each other. And no significant difference
was found. When we employed funnel plots to detect
publication biases, no significant things was found (taking
the analysis of survival and adverse events for example,
Fig. 6a, and Fig. 6b).
Discussion
In this meta-analysis we summarized the efficiency and
safety of vasopressin V2-receptor antagonists (one kind
of vaptans) in cirrhosis patients with ascites from all
related previous studies. vasopressin V2-receptor antagonist
could significantly improve the ascites and low serum
sodium status (or even hyponatremia) of liver cirrhosis
patients. However, no survival benefit was detected,
whether with the administration of vaptans for short-term
or long-term.
Liver disease is a serious and widespread health
problem, especially in Asia, because of the epidemic
of hepatitis (chronic hepatitis B, mainly) [28]. For cirrhosis
patients with ascites, no matter they are in the waiting list
of liver transplantation or could not receive transplantation
because of some objective reasons, symptomatic treatment
is very important. Vaptans was proved to be a kind of
effective aquaretics in SIADH patients [29], heart failure
patients [30]. And according to our analyzed data, vaptans
can also play a remarkable role on cirrhosis patients in
aquaretic effect. Except for patients in three included
studies published as abstract, which did not mention
the data about the aquaretic effect of satavaptan, all of the
other included patients were reported to present an
increase of 24 h urine output after the administration of
vaptans. And we found this effect did not rely on whether
vaptans was employed alone or in combination with
conventional diuretics. In some included studies [17, 18],
ascites patients were reported to show low or even non
response to the use of conventional diuretics at 24 h urine
output. However, vaptans still showed significant aquaretic
effect. So vaptans may be helpful for refractory ascites
patients, who presented low response to conventional
diuretics [31], to reduce ascites volume and the need
for paracentesis, without the generation of more adverse
events by increasing diuretic dose.
Generally, ascites patients had some ascites associated
clinical symptoms, such as abdominal distension, loss of
appetite, breathing difficulty, and so on. These symptoms
may lead to deterioration of quality of life [2]. Because of
the significant aquaretic effect of vaptans, patients in
vaptans groups presented significant decrease in body-
weight and abdominal girth, which was considered to
reflect improvement of the clinical symptoms for ascites
patients. And that meant vaptans could significantly
Fig. 4 The comparison between the vaptans groups and placebo groups about 1-year survival. Studies are identified by the first author’s name
and year of publication. The data of intervention groups would be gathered up as one to make the comparison if there are several dose groups
comparing with one control group. The Odds Ratios are pooled using the fixed effects model. Abbreviation: CI, confidence interval
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Fig. 5 (See legend on next page.)
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improve patients’ quality of life. This improvement is
very important for cirrhosis patients [32].
Serum sodium concentration was proved to be an
very important prognostic indicator for cirrhosis patients
[33]. Low serum sodium concentration frequently
appeared on cirrhosis patients with ascites [34]. Some
previous studies reported that lower serum sodium
concentration, or even hyponatremia, could be associated
with lower survival [35]. So the treatment of correcting
the serum sodium concentration was necessary for cirrho-
sis patients. From the selected studies and the analysis
results we knew, serum sodium concentration was
significantly increased in the vaptans groups, no matter
whether the administration of vaptans was in association
with conventional diuretics or not. And the increment
presented as dose related in some studies. The significant
effect of correcting the serum sodium concentration
derived from the mechanism of vasopressin V2-receptor
antagonists. V2 receptor is expressed principally in main
cells of the renal-collecting-duct system, and its acti-
vation leads to increased resorption of free water [36]. So
vasopressin V2-receptor antagonists may induce a highly
hypotonic diuresis without affecting the excretion of
electrolytes [7], and that leads to the increase of serum
sodium naturally.
Because serum sodium concentration has already been
incorporated into the Model for End-Stage Liver Disease
(MELD) score, and the MELD is currently used as
assessment criteria for patients awaiting liver transplant-
ation [35], the significant increase of serum sodium level
would reduce the score and priority of patients in the
waiting list inevitably. However, it has been proved that
hyponatremia could increase the mortality of periopera-
tive liver transplant [37]. When we just consider trans-
planting patients with hyponatremia preferentially without
correcting the serum sodium actively, it may achieve
negative results for reducing the liver transplant mortality
[38]. So even if it affects the priority, effective medical
management to improve the serum sodium, like the
vasopressin V2 receptor antagonists, remains important in
cirrhosis patients with hyponatremia. Of course the new
and effective aquaretics is also very important for the
cirrhosis patients in some countries in which lots patients
could not receive timely liver transplantation.
What puzzled us was, though the significant effect
on the relief of symptoms and the elevating of serum
sodium concentration, patients’ short-term and long-term
survival did not change much after the administration of
vasopressin V2 receptor antagonists. There were 3 studies
containing 1571 patients and 3 studies containing 419
(See figure on previous page.)
Fig. 5 a The comparison between the vaptans groups and placebo groups about the total adverse events. Studies are identified by the first
author’s name and year of publication. The data of intervention groups would be gathered up as one to make the comparison if there are
several dose groups comparing with one control group. The Risk Ratios are pooled using the fixed effects model. Abbreviation: CI, confidence
interval. b The comparison between the vaptans groups and placebo groups about the serious adverse events. Studies are identified by the first
author’s name and year of publication. The data of intervention groups would be gathered up as one to make the comparison if there are
several dose groups comparing with one control group. The Risk Ratios are pooled using the fixed effects model. Abbreviation: CI, confidence
interval. c The comparison between the vaptans groups and placebo groups about the incidence rate of deterioration of liver function events.
Studies are identified by the first author’s name and year of publication. The data of intervention groups would be gathered up as one to make
the comparison if there are several dose groups comparing with one control group. The Risk Ratios are pooled using the fixed effects model.
Abbreviation: CI, confidence interval
Fig. 6 a Funnel plots to detect publication biases of survival. b Funnel plots to detect publication biases of adverse events
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patients respectively reported the information of 1-year
survival and short-term (2, 4, 12 weeks) survival. The
pooled data did not prove the included vaptans extend
patients’ life. In our opinions, the reasons caused the simi-
lar outcome of survival for all of the included patients
were: 1. The survival data was insufficient as more than a
half of included studies (8 studies) did not provide survival
data. More survival data, especially long-term survival,
was needed. 2. Most included studies did not manage
the analysis and researches by stratifying the patients
according the severity of liver disease. 3. Most of patients
in these RCTs could be categorized as end-stage liver
disease patients, and the prognosis were extremely
poor for these persons. From the analysis of survival data
we could also find that, though it was not significant,
vaptans may extend patients’ life time when it was used
with conventional diuretic (the OR value was 1.44).
Excessive correction of serum sodium concentrations
(>145 mmol/L) was a typical treatment-emergent adverse
event caused by vaptans, and it may cause some serious
consequence, like osmotic demyelination and myelinolysis
[10]. 6 trails reported about 11.1 % patients in the vaptans
group emerged excessive correction of serum sodium at
least one time [18, 20–22]. The RR value was 2.14 when
comparing with placebo group (about 5.5 % patients in
placebo group). It was obviously that treatment with
higher dose vaptans (lixivaptan/VPA-985 300 mg per day;
RWJ-351647 5 mg per day; satavaptan 25 mg per day)
meant higher chance of excessive correction of serum
sodium for cirrhosis patients with ascites. So the dosage
must be good controlled and the change of serum sodium
concentration should be monitored carefully when we
treat cirrhosis patients with vaptans clinically. However,
no patients in these 6 trails retreated from studies and no
serious consequences happened because of the emerging
of excessive of correction of serum sodium concentra-
tions. The liver injury was regarded as another limit of the
vaptan’s clinical application. However, from the analytic
work we found the employment of vaptans would not lead
to deterioration of liver function in cirrhosis patients
with ascites. Although the difference was not significant,
RR value was 0.88 might indicate the incidence rate
of deterioration of liver function may be even smaller
for the patients who used vaptans. To some extent, the
vasopressin V2 receptor antagonists were safe in the
clinical application.
Conclusions
From our analysis we drew a conclusion that, as a kind
of new and effective aquaretics, vasopressin V2 receptor
antagonists could play an effective role in elevating
serum sodium concentration and symptomatic treatment
for cirrhosis patients with ascites, especially for refractory
ascites patients who presented insufficient response to
conventional diuretics. Necessary monitoring must be
adopted when use these vaptans in the clinical in order to
avoid the happening of treatment-emergent adverse
events (like excessive of correction of serum sodium).
Though the analysis of the included studies did not find
evidence of vasopressin V2 receptor antagonists extending
cirrhosis patients’ lifetime, we could not ignore this effect
easily considering the remarkable effects of elevating
serum sodium concentration and improvement of ascites.
Under ideal conditions, more RCTs of each vaptans
focusing on the survival data may be needed.
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